Årsredovisning för 2022 publicerad | Iconovo

Investors
News
Contact

About us
Inhalers
- ICOres
- ICOcap
- ICOpre
- ICOone
- ICOone Nasal
- Patents
Development capabilities
Pipeline
Partner with us
Investors
Search
Menu Menu

Iconovo AB (publ) har publicerat årsredovisning för 2022. Läs årsredovisningen här

Possessing a unique combination

of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

ICONOVO AB

VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B

POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se

Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se

Press releases

Follow us on Linkedin

Iconovo, Arcede Pharma AB and Lund University receive funding from Swelife to...

Study start for Monash University with inhaled oxytocin in ICOone